Cargando...

A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

PURPOSE: Enzastaurin is a selective inhibitor of protein kinase C β. Prior phase I studies did not show increased drug exposures with escalating once daily administration. Limits from gastrointestinal absorption may be overcome by twice daily dosing, potentially improving antitumor effects. EXPERIME...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Kreisl, Teri N., Kim, Lyndon, Moore, Kraig, Duic, Paul, Kotliarova, Svetlana, Walling, Jennifer, Musib, Luna, Thornton, Donald, Albert, Paul S., Fine, Howard A.
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7227612/
https://ncbi.nlm.nih.gov/pubmed/19417015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-3071
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!